Results 51 to 60 of about 327,068 (394)

Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma [PDF]

, 2013
Peer reviewedPublisher ...
Walsh, Garry Michael
core   +2 more sources

Utility of serum periostin in combination with exhaled nitric oxide in the management of asthma

Allergology International, 2017
Type-2/eosinophilic inflammation plays a pivotal role in asthma. The identification of severe type-2/eosinophilic asthma is important for improving the management of patients with asthma.
Tadao Nagasaki, Hisako Matsumoto, Kenji Izuhara, Yoshihiro Kanemitsu, Yuji Tohda, Takahiko Horiguchi, Hideo Kita, Keisuke Tomii, Masaki Fujimura, Akihito Yokoyama, Yasutaka Nakano, Soichiro Hozawa, Isao Ito, Tsuyoshi Oguma, Yumi Izuhara, Tomoko Tajiri, Toshiyuki Iwata, Tetsuji Yokoyama, Akio Niimi, Michiaki Mishima   +19 more
doaj   +1 more source

New and developing non-adrenoreceptor small molecule drugs for the treatment of asthma [PDF]

, 2017
Introduction: Inhaled corticosteroids (ICS) alone or in combination with an inhaled long-acting beta2-agonist (LABA) are the preferred long-term treatment for adults and adolescents with symptomatic asthma.
Thomson, Neil C.
core   +1 more source

Long-Term Efficacy and Clinical Remission After Benralizumab Treatment in Patients with Severe Eosinophilic Asthma: A Retrospective Study

Journal of Asthma and Allergy, 2022
Background Few studies on the long-term efficacy of benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, have been conducted for patients with severe eosinophilic asthma (SEA), especially regarding the improvement of pulmonary function and
T. Numata, Jun Araya, Keitaro Okuda, H. Miyagawa, S. Minagawa, Takeo Ishikawa, Hiromichi Hara, K. Kuwano   +7 more
semanticscholar   +1 more source

We Have to Learn to Do Without Knowing Enough: Anti-Eosinophilic Treatments for Severe Asthma [PDF]

, 2018
Interleukin.5 (IL.5) is the main eosinophilic cytokine that promotes the differentiation, survival, and activation of eosinophils, which are the key inflammatory cells in severe eosinophilic asthma .Thus, it is no surprise that ...
4,, BEGHE', Bianca, Fabbri, Lm3, Papi, A1   +3 more
core   +1 more source

Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma

Allergy. European Journal of Allergy and Clinical Immunology, 2020
Five biologicals have been approved for severe eosinophilic asthma, a well‐recognized phenotype. Systematic reviews (SR) evaluated the efficacy and safety of benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab (alphabetical order) compared to
I. Agache, Jessica Beltran, C. Akdis, M. Akdiş, C. Canelo-Aybar, W. Canonica, T. Casale, T. Chivato, J. Corren, S. D. Del Giacco, T. Eiwegger, D. Firinu, J. Gern, E. Hamelmann, N. Hanania, M. Mäkelä, I. H. Martín, Parameswaran Nair, L. O’Mahony, N. Papadopoulos, A. Papi, Hae‐Sim Park, L. A. Pérez de Llano, M. Posso, Claudio Rocha, S. Quirce, J. Sastre, M. Shamji, Yang Song, Corinna Steiner, J. Schwarze, P. Alonso-Coello, Ó. Palomares, M. Jutel   +33 more
semanticscholar   +1 more source

Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population [PDF]

, 2017
Acknowledgments The authors thank Derek Skinner (Cambridge Research Support Ltd, Oakington, Cambridge, UK) for assistance with data extraction.Peer reviewedPublisher ...
Gibson, Danny, Golam, Sarowar, Hillyer, Elizabeth V, Kerkhof, Marjan, Price, David B, Soriano, Joan B, Tran, Trung N   +6 more
core   +1 more source

Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: Real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype Expression

Journal of Asthma and Allergy, 2021
Background Benralizumab can be utilized as add-on biological treatment of severe eosinophilic asthma. However, so far only a few real-life studies have been published with regard to the use of this anti-IL-5 receptor humanized monoclonal antibody ...
C. Pelaia, C. Crimi, A. Benfante, M. Caiaffa, C. Calabrese, G. E. Carpagnano, D. Ciotta, M. D’Amato, L. Macchia, S. Nolasco, G. Pelaia, S. Pellegrino, N. Scichilone, G. Scioscia, G. Spadaro, G. Valenti, A. Vatrella, N. Crimi   +17 more
semanticscholar   +1 more source

Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma [PDF]

ERJ Open Research, 2021
Within 1 year, 15% of Canadian patients with severe asthma discontinue benralizumab. The reasons for discontinuation are not yet characterised. https://bit.ly/3kaRDlp.
Lawrence Mbuagbaw, Karissa Johnston, Niroshan Sriskandarajah, Stephen G Noorduyn, Stephen G Noorduyn, K Osenenko, A Gendron   +6 more
openaire   +4 more sources

Two years follow-up of relapsing eosinophilic pneumonia with concomitant severe asthma successfully treated with benralizumab: A case report and brief review of the literature

Respiratory Medicine Case Reports, 2023
Relapsing eosinophilic pneumonia and severe eosinophilic asthma are rare and disabling diseases, which share common inflammatory backgrounds and often require long-term systemic steroid therapy.
G. Angeletti, M. Mazzolini, A. Rocca
doaj